- Home
- MTZ vs UTHR Comparison
MTZ vs UTHR Comparison
Compare MTZ & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTZ
- UTHR
- Stock Information
- Founded
- MTZ 1929
- UTHR 1996
- Country
- MTZ United States
- UTHR United States
- Employees
- MTZ N/A
- UTHR N/A
- Industry
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- MTZ Industrials
- UTHR Health Care
- Exchange
- MTZ Nasdaq
- UTHR Nasdaq
- Market Cap
- MTZ 13.6B
- UTHR 20.7B
- IPO Year
- MTZ N/A
- UTHR 1999
- Fundamental
- Price
- MTZ $197.94
- UTHR $454.68
- Analyst Decision
- MTZ Strong Buy
- UTHR Buy
- Analyst Count
- MTZ 22
- UTHR 12
- Target Price
- MTZ $221.86
- UTHR $495.08
- AVG Volume (30 Days)
- MTZ 1.1M
- UTHR 606.4K
- Earning Date
- MTZ 10-30-2025
- UTHR 10-29-2025
- Dividend Yield
- MTZ N/A
- UTHR N/A
- EPS Growth
- MTZ 270.77
- UTHR 16.08
- EPS
- MTZ 4.20
- UTHR 26.38
- Revenue
- MTZ $13,762,473,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- MTZ $15.02
- UTHR $13.68
- Revenue Next Year
- MTZ $9.93
- UTHR $5.63
- P/E Ratio
- MTZ $46.85
- UTHR $17.20
- Revenue Growth
- MTZ 12.99
- UTHR 13.50
- 52 Week Low
- MTZ $99.70
- UTHR $266.98
- 52 Week High
- MTZ $224.03
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- MTZ 44.27
- UTHR 62.72
- Support Level
- MTZ $191.78
- UTHR $430.02
- Resistance Level
- MTZ $202.98
- UTHR $479.50
- Average True Range (ATR)
- MTZ 9.25
- UTHR 14.68
- MACD
- MTZ -1.89
- UTHR 0.39
- Stochastic Oscillator
- MTZ 23.31
- UTHR 64.72
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.